DOCSLIB.ORG

Currently Prescribed Psychotropic Medications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Currently Prescribed Psychotropic Medications CURRENTLY PRESCRIBED PSYCHOTROPIC MEDICATIONS Schizophrenia Depression Anxiety Disorders 1st generation antipsychotics: Tricyclics: Atarax (hydroxyzine) Haldol (haloperidol), *Anafranil (clomipramine) Ativan (lorazepam) Haldol Decanoate Asendin (amoxapine) BuSpar (buspirone) Loxitane (loxapine) Elavil (amitriptyline) *Inderal (propranolol) Mellaril (thioridazine) Norpramin (desipramine) Keppra (levetiracetam) Navane (thiothixene) Pamelor (nortriptyline) *Klonopin (clonazepam) Prolixin (fluphenazine), Prolixin Sinequan (doxepin) Librium (chlordiazepoxide) Decanoate Spravato (esketamine) Serax (oxazepam) Stelazine (trifluoperazine) Surmontil (trimipramine) Thorazine (chlorpromazine) *Tenormin (atenolol) Tofranil (imipramine) MEDICATIONS PSYCHOTROPIC PRESCRIBED CURRENTLY Trilafon (perphenazine) Tranxene (clorazepate) Vivactil (protriptyline) Valium (diazepam) 2nd generation antipsychotics: Zulresso (brexanolone) Vistaril (hydroxyzine) Abilify (aripiprazole) Aristada (aripiprazole) SSRIs: Xanax (alprazolam) Clozaril (clozapine) Celexa (citalopram) *Antidepressants, especially SSRIs, are also used in the treatment of anxiety. Fanapt (iloperidone) Lexapro (escitalopram) Geodon (ziprasidone) *Luvox (fluvoxamine) Invega (paliperidone) Paxil (paroxetine) Stimulants Invega Sustenna (used in the treatment of ADD/ADHD) Prozac (fluoxetine) Perseris (Risperidone injectable) Zoloft (sertraline) Adderall (amphetamine and Latuda (lurasidone) dextroamphetamine) Rexulti (brexpiprazole) MAOIs: Dexedrine (dextroamphetamine) Risperdal (risperidone), Emsam (selegiline) Focalin (dexmethylphenidate) Risperdal Consta Marplan (isocarboxazid) Jornay (methylphenidate Saphris (asenapine) Nardil (phenelzine) hydrochloride) Seroquel (quetiapine) Parnate (tranylcypromine) Ritalin (methylphenidate) Vraylar (cariprazine) (Concerta, Daytrana) Zyprexa (olanzapine) Others: Vyvanse (lisdexamfetamine) Zyprexa Relprevv Trintellix (vortioxetine) app 7/13 *Antidepressants with stimulant Bipolar Disorder Cymbalta (duloxetine) properties, such as Norpramin and Wellbutrin, are also used in the treatment Depakene (valproic acid) Desyrel (trazodone) of ADHD. Depakote (divalproex sodium) Effexor (venlafaxine) Eskalith, Lithobid, Lithonate, Fetzima (levomilnacipran)app 7/13 Non-Stimulants Oleptro (trazodone) Lithotabs (lithium carbonate) (used in the treatment of ADD/ADHD) *Lamictal (lamotrigine) Pristiq (desvenlafaxine) *Neurontin (gabapentin) Remeron (mirtazapine) Intuniv (guanfacine) *Tegretol (carbamazepine) Serzone (nefazodone) Strattera (atomoxetine) *Topamax (topiramate) Viibryd (vilazodone) Trileptal (oxcarbazepine) Wellbutrin (bupropion) Anti-panic Agents Treat Substance Abuse Anti-obsessive Agents Klonopin (clonazepam) Tobacco Dependence Paxil (paroxetine) Wellbutrin (bupropion) Anafranil (clomipramine) Xanax (alprazolam) Chantix (varenicline) Luvox (fluvoxamine) Zoloft (sertraline) Alcohol Dependence Paxil (paroxetine) *Antidepressants are also used in the Vivitrol, Revia or Depade Prozac (fluoxetine) treatment of panic disorder. (naltrexone) Zoloft (sertraline) Campral (acamprosate) Antabuse (disulfiram) Listed above are the brand names, followed by the generic (in parentheses) of commonly Opiate/Narcotic Dependence prescribed psychotropic medications. A second chart on the back of this sheet provides Bunavail (buprenorphine & naloxone) cross-referencing by generic name. Methadose or Dolophine As with all questions about medication, be sure to consult with a prescribing physician or (methadone) pharmacist for any specific questions you may have about dosage, drug interactions, or side Suboxone/Subutex effects. (buprenorphine) *Although this medication has been approved by the FDA for the treatment of other disorders, it has Vivitrol, Revia or Depade not been approved for this particular use. Some evidence of this medication's efficacy for such use does (naltrexone) exist however. This type of medication use is referred to as "off label." Narcan/DAWN Kits (naloxone) Reviewed 3/2020 Generic Name Brand Name Current Uses Generic Name Brand Name Current Uses acamprosate Campral alcohol dependence imipramine Tofranil depression, panic alprazolam Xanax anxiety, panic lamotrigine *Lamictal bipolar disorder amitriptyline Elavil depression isocarboxazid Marplan depression amoxapine Asendin depression levetiracetam Keppra anti-seizure amphetamine and Adderall ADHD, stimulant mood stabilizer dextroamphetamine levomilnacipran Fetzima (app 7/13) depression aripiprazole Abilify schizophrenia, aripiprazole lauroxil Aristada injection depression lisdexamfetamine Vyvanse ADHD, stimulant asenapine Saphris schizophrenia, bipolar disorder Eskalith, Lithobid, lithium carbonate Lithonate, bipolar disorder atenolol *Tenormin anxiety Lithotabs atomoxetine Strattera ADHD, lorazepam Ativan anxiety non-stimulant loxapine Loxitane schizophrenia brexpiprazole Rexulti schizophrenia, lurasidone Latuda schizophrenia depression Methadose, opiate-narcotic brexanolone Zulresso Depression, others methadone Dolophine dependence Ritalin, Concerta buprenorphine Suboxone, Subutex opiate-narcotic methylphenidate Daytrana ADHD, stimulant dependence mirtazapine Remeron depression buprenorphine and Bunavail (app 6/14) opiate-narcotic naloxone dependence naloxone Narcan/DAWN OD antidote Wellbutrin depression, ADHD, bupropion tobacco dependence alcohol / naltrexone Vivitrol, Revia, opiate-narcotic buspirone BuSpar anxiety Depade dependence Carbamazepine *Tegretol bipolar disorder nefazodone Serzone depression cariprazine Vraylar Schizophrenia, nortriptyline Pamelor depression bipolar disorder Zyprexa, chlordiazepoxide Librium anxiety olanzapine Zyprexa Relprevv schizophrenia chlorpromazine Thorazine schizophrenia oxazepam Serax anxiety citalopram Celexa depression, panic, Bipolar anxiety oxcarbazepine *Trileptal disorder clomipramine *Anafranil OCD, depression paliperidone Invega, Invega schizophrenia clonazepam *Klonopin panic, anxiety Sustenna clorazepate Tranxene anxiety depression, panic, paroxetine Paxil OCD, anxiety clozapine Clozaril schizophrenia perphenazine Trilafon schizophrenia desipramine Norpramin depression,ADHD phenelzine Nardil depression desvenlafaxine Pristiq depression propranolol *Inderal anxiety dexmethylphenidate Focalin ADHD, stimulant protriptyline Vivactil depression dextroamphetamine Dexedrine ADHD, stimulant Seroquel diazepam Valium anxiety quetiapine Seroquel XR schizophrenia Risperdal, disulfiram Antabuse alcohol dependence risperidone Risperdal Consta schizophrenia CURRENTLY PRESCRIBED PSYCHOTROPIC MEDICATIONS PSYCHOTROPIC PRESCRIBED CURRENTLY divalproex sodium Depakote bipolar disorder selegiline Emsam depression depression, panic, doxepin Sinequan depression sertraline Zoloft OCD, anxiety duloxetine Cymbalta depression thioridazine Mellaril schizophrenia thiothixene Navane schizophrenia escitalopram Lexapro Depression topiramate *Topamax bipolar disorder esketamine Spravato Depression, other tranylcypromine Parnate depression fluoxetine Prozac depression, OCD, Desyrel panic, anxiety trazodone Oleptro depression fluphenazine Prolixin, Prolixin schizophrenia Decanoate trifluoperazine Stelazine schizophrenia fluvoxamine *Luvox OCD, depression, trimipramine Surmontil depression panic, anxiety valproic acid Depakene bipolar disorder gabapentin *Neurontin bipolar disorder varenicline Chantix tobacco dependence guanfacine Intuniv ADHD, non-stimulant venlafaxine Effexor depression haloperidol Haldol, schizophrenia vilazodone Viibryd depression Haldol Decanoate hydroxyzine Vistaril, Atarax anxiety vortioxetine Trintellix depression ziprasidone Geodon Schizophrenia iloperidone Fanapt schizophrenia *Although this medication has been approved by the FDA for the treatment of other disorders, it has not been approved for this particular use. Some evidence of this medication's efficacy for such use does exist however. This type of medication use is referred to as "off label." .
Load more

Recommended publications
  • Addictions and the Brain
    9/18/2012 Addictions and the Brain TAAP Conference September 14, 2012 Acknowledgements • La Hacienda Treatment Center • American Society of Addiction Medicine • National Institute of Drug Abuse © 2012 La Hacienda Treatment Center. All rights reserved. 1 9/18/2012 Definition • A primary, progressive biochemical, psychosocial, genetically transmitted chronic disease of relapse who’s hallmarks are denial, loss of control and unmanageability. DSM IV Criteria for dependency: At least 3 of the 7 below 1. Withdrawal 2. Tolerance 3. The substance is taken in larger amounts or over a longer period than was intended. 4. There is a persistent desire or unsuccessful efforts to cut down or control substance use. 5. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects. 6. Important social, occupational, or recreational activities are given up or reduced because of the substance use. 7. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. © 2012 La Hacienda Treatment Center. All rights reserved. 2 9/18/2012 Dispute between behavior and disease Present understanding of the Hypothalamus location of the disease hypothesis. © 2012 La Hacienda Treatment Center. All rights reserved. 3 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 4 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 5 9/18/2012 Dispute regarding behavior versus disease © 2012 La Hacienda Treatment Center. All rights reserved. 6 9/18/2012 © 2012 La Hacienda Treatment Center.
    [Show full text]
  • NH Healthy Families Preferred Drug List (PDL) Is the List of Covered Drugs
    Pharmacy Program NH Healthy Families is committed to providing appropriate, high quality, and cost effective drug therapy to all NH Healthy Families members. NH Healthy Families works with providers and pharmacists to ensure that medications used to treat a variety of conditions and diseases are covered. NH Healthy Families covers prescription medications and certain over-the-counter (OTC) medications when ordered by a practitioner. The pharmacy program does not cover all medications. Some medications require prior authorization (PA) or have limitations on age, dosage, and maximum quantities. Preferred Drug List The NH Healthy Families Preferred Drug List (PDL) is the list of covered drugs. The PDL applies to drugs members can receive at retail pharmacies. The NH Healthy Families PDL is continually evaluated by the NH Healthy Families Pharmacy and Therapeutics (P&T) Committee to promote the appropriate and cost- effective use of medications. The Committee is composed of the NH Healthy Families Medical Director, NH Healthy Families Pharmacy Director, and several New Hampshire physicians, pharmacists, and other healthcare professionals. Pharmacy Benefit Manager NH Healthy Families works with Envolve Pharmacy Solutions to process pharmacy claims for prescribed drugs. Some drugs on the NH Healthy Families PDL may require PA, and Envolve Pharmacy Solutions is responsible for administering this process. Envolve Pharmacy Solutions is our Pharmacy Benefit Manager (PBM). Specialty Drugs NH Healthy Families contracts with a number of specialty pharmacies, such as AcariaHealth Specialty Pharmacy, to ensure members have adequate access to the specialty drugs they require. Specialty drugs, such as biopharmaceuticals and injectables, may require PA to be approved for payment by NH Healthy Families.
    [Show full text]
  • ADHD Parents Medication Guide Revised July 2013
    ADHD Parents Medication Guide Revised July 2013 Attention-Deficit/Hyperactivity Disorder Prepared by: American Academy of Child & Adolescent Psychiatry and American Psychiatric Association Supported by the Elaine Schlosser Lewis Fund Physician: ___________________________________________________ Address: ___________________________________________________ ___________________________________________________ ___________________________________________________ Phone: ___________________________________________________ Email: ___________________________________________________ ADHD Parents Medication Guide – July 2013 2 Introduction Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by difficulty paying attention, excessive activity, and impulsivity (acting before you think). ADHD is usually identified when children are in grade school but can be diagnosed at any time from preschool to adulthood. Recent studies indicate that almost 10 percent of children between the ages of 4 to 17 are reported by their parents as being diagnosed with ADHD. So in a classroom of 30 children, two to three children may have ADHD.1,2,3,4,5 Short attention spans and high levels of activity are a normal part of childhood. For children with ADHD, these behaviors are excessive, inappropriate for their age, and interfere with daily functioning at home, school, and with peers. Some children with ADHD only have problems with attention; other children only have issues with hyperactivity and impulsivity; most children with ADHD have problems with all three. As they grow into adolescence and young adulthood, children with ADHD may become less hyperactive yet continue to have significant problems with distraction, disorganization, and poor impulse control. ADHD can interfere with a child’s ability to perform in school, do homework, follow rules, and develop and maintain peer relationships. When children become adolescents, ADHD can increase their risk of dropping out of school or having disciplinary problems.
    [Show full text]
  • Reveiw Week 3 Final with Questions
    REVIEW 3 SOMATIZATION AND RELATED DISORDERS SOMATIZATION AND RELATED DISORDERS SOMATIZATION ▸ Psychological problems or concerns that are converted into and communicated as physical distress ▸ Anxiety is either Conscious or Unconscious ▸ Physical Illness is Real SOMATIZATION AND RELATED DISORDERS - SSD SOMATIC SYMPTOM DISORDER A. One or more somatic symptoms that are distressing or result in significant disruption of daily life B. Excessive thoughts, feelings, or behaviors related to the somatic symptoms or associated health concerns as manifested by at least one of the following 1. Disproportionate and persistent thoughts about the seriousness or one’s symptoms 2. Persistently high level of anxiety about health or symptoms 3. Excessive time and energy devoted to these symptoms or health concerns C. Although any one somatic symptom may not be continuously present, the state of being symptomatic is persistent (typically more than 6 months) SOMATIZATION AND RELATED DISORDERS - SSD TREATMENT ▸ Regular office visits with the same physician ▸ Psychotherapy ▸ Validate the patient’s feelings/experience of symptoms SOMATIZATION AND RELATED DISORDERS - ILLNESS ANXIETY DISORDER ILLNESS ANXIETY DISORDER A. Formerly hypochondriasis B. Preoccupation with having or acquiring a serious illness C. Somatic symptoms are not present or, if present, are only mild in intensity. If another medical condition is present or there is a high risk for developing a medical condition (strong FH), the preoccupation is clearly excessive or disproportionate D. There is a high level of anxiety about health, and the individual is easily alarmed about personal health status (preoccupation with idea one is sick) E. The individual performs excessive health-related behaviors (checking body) or exhibits maladaptive avoidance (avoids doctors) F.
    [Show full text]
  • Medications and Alcohol Craving
    Medications and Alcohol Craving Robert M. Swift, M.D., Ph.D. The use of medications as an adjunct to alcoholism treatment is based on the premise that craving and other manifestations of alcoholism are mediated by neurobiological mechanisms. Three of the four medications approved in the United States or Europe for treating alcoholism are reported to reduce craving; these include naltrexone (ReVia™), acamprosate, and tiapride. The remaining medication, disulfiram (Antabuse®), may also possess some anticraving activity. Additional medications that have been investigated include ritanserin, which has not been shown to decrease craving or drinking levels in humans, and ondansetron, which shows promise for treating early onset alcoholics, who generally respond poorly to psychosocial treatment alone. Use of anticraving medications in combination (e.g., naltrexone plus acamprosate) may enhance their effectiveness. Future studies should address such issues as optimal dosing regimens and the development of strategies to enhance patient compliance. KEY WORDS: AOD (alcohol and other drug) craving; anti alcohol craving agents; alcohol withdrawal agents; drug therapy; neurobiological theory; alcohol cue; disulfiram; naltrexone; calcium acetylhomotaurinate; dopamine; serotonin uptake inhibitors; buspirone; treatment outcome; reinforcement; neurotransmitters; patient assessment; literature review riteria for defining alcoholism Results of craving research are often tions (i.e., pharmacotherapy) to improve vary widely. Most definitions difficult to interpret,
    [Show full text]
  • Clomipramine | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Clomipramine This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Anafranil Brand Names: Canada Anafranil; MED ClomiPRAMINE; TARO-Clomipramine Warning Drugs like this one have raised the chance of suicidal thoughts or actions in children and young adults. The risk may be greater in people who have had these thoughts or actions in the past. All people who take this drug need to be watched closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur. This drug is not approved for use in all children. Talk with the doctor to be sure that this drug is right for your child. What is this drug used for? It is used to treat obsessive-compulsive problems. It may be given to you for other reasons. Talk with the doctor. Clomipramine 1/8 What do I need to tell my doctor BEFORE I take this drug? If you have an allergy to clomipramine or any other part of this drug. If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have had a recent heart attack. If you are taking any of these drugs: Linezolid or methylene blue.
    [Show full text]
  • Drug Use Evaluation: Antipsychotic Utilization in Schizophrenia Patients
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Drug Use Evaluation: Antipsychotic Utilization in Schizophrenia Patients Research Questions: 1. How many schizophrenia patients are prescribed recommended first-line second-generation treatments for schizophrenia? 2. How many schizophrenia patients switch to an injectable antipsychotic after stabilization on an oral antipsychotic? 3. How many schizophrenia patients are prescribed 2 or more concomitant antipsychotics? 4. Are claims for long-acting injectable antipsychotics primarily billed as pharmacy or physician administered claims? 5. Does adherence to antipsychotic therapy differ between patients with claims for different routes of administration (oral vs. long-acting injectable)? Conclusions: In total, 4663 schizophrenia patients met inclusion criteria, and approximately 14% of patients (n=685) were identified as treatment naïve without claims for antipsychotics in the year before their first antipsychotic prescription. Approximately 45% of patients identified as treatment naïve had a history of remote antipsychotic use, but it is unclear if antipsychotics were historically prescribed for schizophrenia. Oral second-generation antipsychotics which are recommended as first-line treatment in the MHCAG schizophrenia algorithm were prescribed as initial treatment in 37% of treatment naive patients and 28% of all schizophrenia patients. Recommended agents include risperidone, paliperidone, and aripiprazole. Utilization of parenteral antipsychotics was limited in patients with schizophrenia. Overall only 8% of patients switched from an oral to an injectable therapy within 6 months of their first claim. Approximately, 60% of all schizophrenia patients (n=2512) had claims for a single antipsychotic for at least 12 continuous weeks and may be eligible to transition to a long-acting injectable antipsychotic.
    [Show full text]
  • Schizophrenia Care Guide
    August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic
    [Show full text]
  • Medicines That Affect Fluid Balance in the Body
    the bulk of stools by getting them to retain liquid, which encourages the Medicines that affect fluid bowels to push them out. balance in the body Osmotic laxatives e.g. Lactulose, Macrogol - these soften stools by increasing the amount of water released into the bowels, making them easier to pass. Older people are at higher risk of dehydration due to body changes in the ageing process. The risk of dehydration can be increased further when Stimulant laxatives e.g. Senna, Bisacodyl - these stimulate the bowels elderly patients are prescribed medicines for chronic conditions due to old speeding up bowel movements and so less water is absorbed from the age. stool as it passes through the bowels. Some medicines can affect fluid balance in the body and this may result in more water being lost through the kidneys as urine. Stool softener laxatives e.g. Docusate - These can cause more water to The medicines that can increase risk of dehydration are be reabsorbed from the bowel, making the stools softer. listed below. ANTACIDS Antacids are also known to cause dehydration because of the moisture DIURETICS they require when being absorbed by your body. Drinking plenty of water Diuretics are sometimes called 'water tablets' because they can cause you can reduce the dry mouth, stomach cramps and dry skin that is sometimes to pass more urine than usual. They work on the kidneys by increasing the associated with antacids. amount of salt and water that comes out through the urine. Diuretics are often prescribed for heart failure patients and sometimes for patients with The major side effect of antacids containing magnesium is diarrhoea and high blood pressure.
    [Show full text]
  • (Orion) 5 Mg Tablets Buspirone (Orion) 10 Mg Tablets
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME Buspirone (Orion) 5 mg tablets Buspirone (Orion) 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg buspirone hydrochloride. Each tablet contains 10 mg buspirone hydrochloride. Excipient with known effect: 5 mg tablet: Each tablet contains 59.5 mg lactose (as monohydrate) 10 mg tablet: Each tablet contains 118.9 mg lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. 5 mg tablet: White or almost white, oval tablets debossed with ‘ORN 30’ on one side and a score on the other side. The tablet can be divided into equal doses. 10 mg tablet: White or almost white, oval tablets debossed with ‘ORN 31’ on one side and a score on the other side. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Buspirone hydrochloride is indicated for the management of anxiety with or without accompanying depression in adults. Buspirone hydrochloride is indicated for the management of anxiety disorders or the short- term relief of symptoms of anxiety with or without accompanying depression. 4.2 Posology and method of administration The usual starting dose is 5 mg given three times daily. This may be titrated according to the needs of the patient and the daily dose increased by 5 mg increments every two or three days depending upon the therapeutic response to a maximum daily dose of 60 mg. After dosage titration the usual daily dose will be 20 to 30 mg per day in divided doses.
    [Show full text]
  • MODERN INDICATIONS for the USE of OPIPRAMOL Krzysztof Krysta1, Sławomir Murawiec2, Anna Warchala1, Karolina Zawada3, Wiesław J
    Psychiatria Danubina, 2015; Vol. 27, Suppl. 1, pp 435–437 Conference paper © Medicinska naklada - Zagreb, Croatia MODERN INDICATIONS FOR THE USE OF OPIPRAMOL Krzysztof Krysta1, Sławomir Murawiec2, Anna Warchala1, Karolina Zawada3, Wiesław J. Cubała4, Mariusz S. Wiglusz4, Katarzyna Jakuszkowiak-Wojten4, Marek Krzystanek5 & Irena Krupka-Matuszczyk1 1Department of Psychiatry and Psychotherapy, Medical University of Silesia, Katowice, Poland 2“Dialogue” Therapy Centre, Warsaw, Poland 3Department of Pneumonology, Medical University of Silesia, Katowice, Poland 4Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Poland 5Department of Rehabilitation Psychiatry, Medical University of Silesia, Katowice, Poland SUMMARY Opipramol is considered as a pharmacological agent that does not fit the classification taking into account the division of antidepressants, antipsychotics and anxiolytics. It has a structure related to tricyclic antidepressants but it has a different mechanism of action, i.e. binding to sigma1 and to sigma2 sites. It has been regarded as an effective drug in general anxiety disorders together with other agents like SSRI`s, SNRI`s, buspirone and pregabalin for many years. It can however also be indicated in other conditions, e.g. it may be used as a premedication in the evening prior to surgery, positive results are also observed in psychopharmacological treatment with opipramol in somatoform disorders, symptoms of depression can be significantly reduced in the climacteric syndrome. The latest data from literature present also certain dangers and side effects, which may result due to opipramol administration. Mania may be induced not only in bipolar patients treated with opipramol, but it can be an adverse drug reaction in generalized anxiety disorder. This analysis shows however that opipramol is an important drug still very useful in different clinical conditions.
    [Show full text]
  • FDA Approved Drugs with Broad Anti-Coronaviral Activity Inhibit SARS-Cov-2 in Vitro
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.25.008482; this version posted March 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro Stuart Weston1, Rob Haupt1, James Logue1, Krystal Matthews1 and Matthew B. Frieman*1 1 - Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 W. Baltimore St., Room 380, Baltimore, MD, 21201, USA *Corresponding author. Email: [email protected] Key words: SARS-CoV-2, nCoV-2019, COVID-19, drug repurposing, FDA approved drugs, antiviral therapeutics, pandemic, chloroquine, hydroxychloroquine AbstraCt SARS-CoV-2 emerged in China at the end of 2019 and has rapidly become a pandemic with over 400,000 recorded COVID-19 cases and greater than 19,000 recorded deaths by March 24th, 2020 (www.WHO.org) (1). There are no FDA approved antivirals or vaccines for any coronavirus, including SARS-CoV-2 (2). Current treatments for COVID-19 are limited to supportive therapies and off-label use of FDA approved drugs (3). Rapid development and human testing of potential antivirals is greatly needed. A potentially quicker way to test compounds with antiviral activity is through drug re-purposing (2, 4). Numerous drugs are already approved for use in humans and subsequently there is a good understanding of their safety profiles and potential side effects, making them easier to test in COVID-19 patients.
    [Show full text]